http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111410651-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2019-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111410651-B |
| titleOfInvention | Salts of tyrosine kinase inhibitors and crystalline forms thereof |
| abstract | The present invention relates to N-(5-((4-(7-cyano-1,3-dimethyl-1H-indol-5-yl)pyrimidin-2-yl)amino represented by the following formula (I) )-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) pharmaceutically acceptable salts of acrylamide, specifically mesylate and formula (I) The crystal form of the mesylate salt of the compound, and the preparation method thereof, the pharmaceutical preparation comprising the above-mentioned salt and the crystal form, and the application thereof in the preparation of a medicine for the treatment and/or prevention of a disease mediated by EGFR . |
| priorityDate | 2019-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 200.